TickerHumSide-by-side comparison
AbbVie vs Biogen
As of Nov 11, 2026, P/E is 50.4x for AbbVie vs 109.3x for Biogen; P/S is 7.8x for AbbVie vs 3.6x for Biogen; revenue growth is 10.7% for AbbVie vs 2.3% for Biogen; net margin is 15.7% for AbbVie vs 3.4% for Biogen.
What stands out
- AbbVie is cheaper on earnings: 50.4x P/E vs 109.3x for Biogen.
- Biogen's shares did better over the past year: +56.4% vs +25.5% for AbbVie.
Key metrics
| Metric | ABBV | BIIB |
|---|---|---|
| Price | $292.77 | $252.57 |
| Market cap | $517.5B | $37.33B |
| P/E | 50.4x (#1) | 109.3x (#2) |
| P/S | 7.8x (#2) | 3.6x (#1) |
| Revenue growth | 10.7% (#1) | 2.3% (#2) |
| Operating margin | 32.2% (#1) | — |
| Net margin | 15.7% (#1) | 3.4% (#2) |
| Debt / equity | — | 0.39 (#1) |
| 1-year return | +25.5% (#2) | +56.4% (#1) |
| Research score | 62/100 (#1) | 53/100 (#2) |
Higher is better for growth, margins, one-year return and overall score; lower is better for valuation and debt ratios. Ties share a rank and missing values are excluded.
Company research
- AbbVie Inc. (ABBV) — Drug Manufacturers—General
- Biogen Inc. (BIIB) — Drug Manufacturers—General